To include your compound in the COVID-19 Resource Center, submit it here.

Bellicum falls on T cell therapy U.S. trial holds

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) fell $2.12 (26%) to $6.08 on Wednesday after it said FDA placed a clinical hold on U.S. trials of the company's adjunct, safety switch-containing T cell

Read the full 307 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE